This product is a recombinant mouse anti-HIV-1 monoclonal antibody (BAT085). BAT085 specifically binds to CD4 binding site of gp120 and can be potentially used in the treatment studies of acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies.
Figure 1 mAb-induced gpl20 dissociation.
The cells were pelleted, and the supernatant was spun through 0.22-/xm filters to remove cell debris and treated with NP-40, 1% final concentration. Gp120-mAb complexes in the supernatants were then denatured to prevent interference of gp120 detection by bound Ig, and gp120 concentration was measured by ELISA. Each bar represents the mean signal obtained from duplicate ELISA wells, and the dotted line represents the level of spontaneous gpl20 dissociation.
Human Immunodeficiency Virus Type 1 Neutralization Is Determined by Epitope Exposure on the gp120 Oligomer
Figure 2. Inhibition of the binding of biotinylated BAT085 (△) to captured HIV-1 IIIB gpl20 in ELISA.
Fung, M. S., Sun, C. R., Gordon, W. L., Liou, R. S., Chang, T. W., Sun, W. N., ... & Ho, D. D. (1992). Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. Journal of virology, 66(2), 848-856.
Figure 3 mAb neutralization of HIV-1.
A stock of virus previously titered on HeLa-CD4-LTR LacZ cells and known to give 200 infected cells/well in 20/zl was incubated for 2 h with mAbs at the concentrations shown in the figure before washing and trypsinization to remove noninternalized virions. The cells were subsequently cultured for 24 h at 37~ before fixation and staining with X-Gal for 4 h at 37~ The cells were then fixed overnight, and the blue loci were counted by eye under magnification. Each point represents the mean of triplicate wells, and the vertical bars indicate +_ 1 SD.
Human Immunodeficiency Virus Type 1 Neutralization Is Determined by Epitope Exposure on the gp120 Oligomer
Figure 4 is a plot showing the relative effectiveness of four of the monoclonal antibodies of the invention in neutralizing HIV-1 infection of H9 cells.
The percentage of infected cells was determined thirteen days after infection.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-380 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone VRC06); scFv Fragment | Neut, FuncS | Human scFv |
PFBW-160 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone F105); Fab Fragment | FC, Neut | Human Fab |
PFBW-178 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone b12); Fab Fragment | Neut, ELISA | Human Fab |
MRO-3591CQ-S(P) | Mouse Anti-HIV-1 gp120 Recombinant Antibody (clone D21); scFv Fragment | ELISA, Block | Mouse scFv |
MRO-3592CQ-S(P) | Mouse Anti-HIV-1 gp120 Recombinant Antibody (clone 8F101); scFv Fragment | ELISA, FC | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PABZ-060 | Mouse Anti-HIV-1 gp120 Recombinant Antibody (clone 50.1) | Neut | Mouse IgG2a, κ |
PABZ-164 | Human Anti-HIV-1 gp120 Recombinant Antibody (PABZ-164) | ELISA, Neut | Human IgG |
PABZ-165 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone GL-VRC01) | Neut | Human IgG |
PABL-520 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 44-VRC13.01) | Neut | Human IgG |
PABL-521 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 45-46M2) | ELISA, Neut | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBZ-210 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 19.3H-L1); scFv Fragment | Neut | Human scFv |
PSBW-160 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone F105); scFv Fragment | FC, Neut | Human scFv |
PSBW-178 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone b12); scFv Fragment | Neut, ELISA | Human scFv |
FAMAB-0177CQ-F(E) | Human Anti-HIV-1 gp120 Recombinant Antibody (clone BAT123); Fab Fragment | Neut | Chimeric (mouse/human) Fab |
FAMAB-0178CQ-F(E) | Human Anti-HIV-1 gp120 Recombinant Antibody (clone C beta 1); Fab Fragment | WB, Neut | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-028LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-028LC-VHH) | ELISA | Single domain antibody |
MRO-029LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-029LC-VHH) | ELISA | Single domain antibody |
MRO-030LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-030LC-VHH) | ELISA | Single domain antibody |
MRO-031LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-031LC-VHH) | ELISA | Single domain antibody |
MRO-032LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-032LC-VHH) | ELISA | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-135LC | Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) | ELISA, WB, Neut | Chimeric antibody (mouse/human) |
MRO-135LC-S(P) | Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) | ELISA, WB | Chimeric antibody (mouse/human) |
MRO-135LC-F(E) | Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) | ELISA, WB | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-172LC | Human Anti-HIV-1 gp120 Recombinant Antibody (MRO-172LC) | ELISA | Human IgG1, κ |
MRO-173LC | Human Anti-HIV-1 gp120 Recombinant Antibody (MRO-173LC) | ELISA | Human IgG1, κ |
MRO-174LC | Human Anti-HIV-1 gp120 Recombinant Antibody (MRO-174LC) | ELISA | Human IgG1, κ |
MRO-175LC | Human Anti-HIV-1 gp120 Recombinant Antibody (MRO-175LC) | ELISA | Human IgG1, κ |
MRO-176LC | Human Anti-HIV-1 gp120 Recombinant Antibody (MRO-176LC) | ELISA | Human IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-041LC-S(P) | Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (D59/A2) | ELISA | Mouse antibody |
MRO-042LC-S(P) | Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (F58/H3) | ELISA | Mouse antibody |
MRO-043LC-S(P) | Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (P1/D12) | ELISA | Mouse antibody |
MRO-044LC-S(P) | Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (P4/D10) | ELISA | Mouse antibody |
MRO-045LC-S(P) | Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (A47/B1) | ELISA | Mouse antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-4220 | Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) | WB, ELISA | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PABX-101-S(P) | Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG9); scFv Fragment | WB, ELISA, FuncS | Human scFv |
There are currently no Customer reviews or questions for MRO-134LC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.